The Thames Valley Strategic Clinical Network launches a new report calling for improvements in neurological services provided in the community.
Results from two trials of an aggressive form of stem cell therapy indicate the treatment may have long-term benefits.
Preliminary results announced in a company press release report that opicinumab (also known as anti-LINGO-1 and BIIB033) failed to improve disability, assessed by a combination of physical and cognitive measures.
Researchers in Canada have identified a gene that appears to significantly increase the risk of developing a rare rapidly progressing form of MS.
A diet that mimics the effects of fasting may have a role in managing MS according to new research.
A study has found wide variation in how much palliative care and neurological teams provide joined-up services at eight sites in England and Wales. There was least coordination in services for people with MS.
An international survey shows that too many people with MS are leaving employment earlier than necessary.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that a licence should be granted for daclizumab for the treatment of relapsing MS.
We're pleased to announce that, after a hugely successful first year, the QuDoS awards, highlighting innovation and excellence in MS services, are now open for nominations for 2016.
According to a new report published today by the MS Trust, growing pressures on NHS services mean people with progressive MS get much less support from specialist health professionals than people with relapsing remitting MS. As well as seeing health professionals less frequently, many people with progressive MS report being ‘abandoned’ by specialist services just as they enter the progressive phase of the disease, marked by complex symptoms and increasing disability.